A Decade Of Determination: A Scientist's Perspective On Advancing AAV Producer Cell Lines
By Bingnan Gu, PhD, MBA, Senior Director, R&D, Viral Vector and Cell Therapy and Vijetha Bhat, Cell & Gene Technical Expert, Licensing
If you think gene therapy manufacturing is mostly a biology problem, this account will reframe your thinking. Scaling adeno-associated virus (AAV) production consistently and cost-effectively turns out to be as much about organizational persistence and scientific honesty as it is about cell line design.
The story starts in 2016 with a CHO-based system that looked promising and wasn't. By 2018, it became clear the platform wouldn't deliver, and the team made the call to stop and pivot to HEK293. That decision wasn't clean or comfortable, but it was right.
What followed was years of steady, rarely straightforward progress. AAV biology introduces real tension between productivity and cell health, particularly because some viral components are toxic to the cells producing them. A key focus became inducible expression systems, controlling precisely when cells switch into production mode. Early proof-of-concept results were encouraging. Turning that into a stable, scalable platform took considerably longer.
The broader lesson here is that no single team solves this alone. Internal expertise, external collaboration, and a willingness to abandon sunk costs all matter.
Access the full account to see how a decade of iteration in AAV manufacturing translates into platform decisions you'll face in your own program.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.